David Taylor

David Taylor is a highly experienced scientist currently serving as a Senior Scientist - CMC at Elusys Therapeutics, Inc., where responsibilities include spearheading statistical analysis for lot release and stability specifications and collaborating with regulatory leadership on eCTD documents for commercial product life cycle management. Prior to this role, David held the position of Senior Scientist - Translational Scientist at NightHawk Biosciences, leading the development of antibody therapeutics for botulinum neurotoxin poisoning. David's academic foundation includes a PhD in Molecular Biology from Cornell University and a Bachelor's degree in Biology from Hampden-Sydney College, with significant research experience, including epigenetic landscape characterization and cost-saving enzyme purification during a postdoctoral tenure at Yale University.